acetylcysteine has been researched along with Parkinson Disease in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.35) | 18.2507 |
| 2000's | 28 (32.94) | 29.6817 |
| 2010's | 47 (55.29) | 24.3611 |
| 2020's | 8 (9.41) | 2.80 |
| Authors | Studies |
|---|---|
| Akaike, A; Izumi, Y; Katsuki, H; Kume, T; Sawada, H; Shimohama, S; Yamamoto, N | 1 |
| Feng, JH; Hu, XL; Lin, J; Lv, XY; Wang, BL; Wang, H; Xiong, F; Ye, WC; Zhang, XQ | 1 |
| Af Bjerkén, S; Axelsson, J; Ericsson, M; Jakobson Mo, S; Johansson, J; Laterveer, R; Ögren, M; Orädd, G; Virel, A | 1 |
| Fay-Karmon, T; Gutman-Sharabi, N; Halperin, R; Khashab, R; Landau, R; Leibowitz, A; Shabtai, Z; Sharabi, Y | 1 |
| Goldstein, DS; Isonaka, R; Jinsmaa, Y; Sharabi, Y | 1 |
| Martinez-Banaclocha, MA | 2 |
| Monti, DA; Newberg, AB | 1 |
| Brandel, J; Dexter, DT; Elson, JL; Fairooz, S; Hubscher-Bruder, V; Lewis, FW; Pienaar, IS; Smith, D; Soundararajan, M; Tétard, D | 1 |
| Furlong, TM; Gibson, AS; Keefe, KA | 1 |
| D'Acunto, CW; Gonzalez, G; Grúz, J; Kaňovský, P; Strnad, M | 1 |
| Airavaara, M; Albert, K; Myöhänen, TT; Savolainen, MH | 1 |
| Chen, ZA; Hsiao, IT; Hsu, CH; Huang, SL; Kung, MP; Lin, KJ; Weng, CC; Wey, SP; Yen, TC | 1 |
| Cloyd, JC; Coles, LD; Kartha, RV; Mishra, UR; Öz, G; Sullivan, KM; Terpstra, M; Tuite, PJ | 1 |
| Ito, Y; Kimura, M; Kojima, W; Koyano, F; Matsuda, N; Mishima, M; Mizushima, T; Queliconi, BB; Takagi, K; Tanaka, K; Yamano, K | 1 |
| Elson, JL; Kochaj, R; Pienaar, IS; Reynolds, R | 1 |
| Alstrup, AKO; Doudet, DJ; Glud, AN; Kirik, D; Landau, AM; Landeck, N; Lillethorup, TP; Nielsen, EHT; Noer, O; Orlowski, D; Schacht, AC; Sørensen, JCH | 1 |
| Af Bjerkén, S; Dudka, I; Laterveer, R; Virel, A | 1 |
| Bazzan, AJ; Bowens, BK; Chervoneva, I; Intenzo, C; Kremens, D; Liang, TW; Monti, DA; Newberg, AB; Wintering, NA; Zabrecky, G; Zhong, L | 1 |
| Huang, KX; Le, WD; Shen, YF; Tang, Y; Zhang, XJ | 1 |
| Izumi, Y | 1 |
| Bury, A; Dexter, DT; Elson, JL; Harrison, IF; Pienaar, IS; Simon, AK; Woll, P | 1 |
| Czarnecka, A; Domin, H; Jantas, D; Konieczny, J; Kuter, K; Lasoń, W; Lenda, T; Lorenc-Koci, E; Śmiałowska, M | 1 |
| Bai, L; Chen, Q; Hu, X; Wu, J; Zhang, H; Zhang, L; Zhang, Y | 1 |
| Ahmad, F; Durgadoss, L; Nidadavolu, P; Ravindranath, V | 1 |
| Anand, S; Banerjee, P; Bir, A; Cappai, R; Chakrabarti, S; Khemka, VK; Sahoo, A; Sen, O | 1 |
| Bhatelia, K; Prajapati, P; Singh, K; Singh, R; Sripada, L | 1 |
| Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P | 1 |
| Glass, GA; Jones, DP; Katz, M; Orr, A; Park, Y; Swanson, RA; Won, SJ | 1 |
| Elson, JL; Pienaar, IS; Yates, A | 1 |
| Crum, WR; Dexter, DT; Harrison, IF; Vernon, AC | 1 |
| Aprigliano, S; Carresi, C; Isidoro, C; Janda, E; Lascala, A; Mollace, V; Morani, F; Musolino, V; Parafati, M; Russo, V; Savoia, C; Ziviani, E | 1 |
| Martínez-Banaclocha, M | 1 |
| Bazzan, AJ; Bowen, B; Cai, J; Iacovitti, L; Intenzo, CM; Kremens, D; Liang, TW; Monti, DA; Newberg, AB; Wei, X; Wintering, NA; Zabrecky, G; Zhong, L | 1 |
| Chung, IF; Fann, MJ; Jiang, JH; Kao, LS; Wu, PC; Yang, TC | 1 |
| Bentea, E; Churchill, MJ; Deneyer, L; Hood, RL; Massie, A; Meshul, CK; Moore, C; Verbruggen, L | 1 |
| Bagh, MB; Banerjee, K; Chakrabarti, S; Jana, S; Maiti, AK; Roy, A | 1 |
| Jankovic, J; Kondo, S; Le, W; Pan, T; Xie, W; Zhu, W | 1 |
| Chen, SD; Ding, JQ; Hong, Z; Pan, J; Sheng, CY; Wang, G; Xiao, Q; Yang, HQ | 1 |
| Chen, B; Xu, SL; Zhou, M | 1 |
| Andersen, JK; Jankovic, J; Kaur, D; Le, W; Li, X; Luo, F; Xie, W; Zhu, W | 1 |
| Kubo, M; Obata, F; Ohta, E | 1 |
| Jackson, T; Jengelley, TA; Jnobaptiste, R; McNaught, KS | 1 |
| Guo, Y; Janokovic, J; Le, W; Li, C; Li, X; Xie, W | 1 |
| Aleyasin, H; Bevilacqua, L; Callaghan, S; Chen, CX; Chhabra, S; Fon, EA; Harper, ME; Hewitt, SJ; Irrcher, I; Jahani-Asl, A; Kim, RH; Lutz, AK; MacLaurin, JG; Mak, TW; McBride, HM; Park, DS; Phillips, M; Rippstein, P; Rizzu, P; Rousseaux, MW; Seifert, EL; Slack, RS; Winklhofer, KF | 1 |
| Adame, A; Clark, J; Clore, EL; Masliah, E; Simon, DK; Zheng, K | 1 |
| Arawaka, S; Fukushima, S; Hara, S; Kato, T; Koyama, S; Machiya, Y; Sakamoto, M; Sato, H | 1 |
| Ahn, T; Bae, N; Chung, S; Ko, H; Oh, H; Oh, MS; Park, G; Yang, HO | 1 |
| Antkiewicz-Michaluk, L; Domin, H; Konieczny, J; Lenda, T; Lorenc-Koci, E; Smiałowska, M; Wardas, J | 1 |
| Caruana, M; Giese, A; Hillmer, A; Högen, T; Levin, J; Vassallo, N | 1 |
| Adler, BL; Berman, AE; Brennan, AM; Chan, WY; Edling, Y; Kauppinen, TM; Reyes, RC; Suh, SW; Swanson, RA | 1 |
| Almeida, L; Barbosa, RM; Laranjinha, J; Nunes, C | 1 |
| Artiukhina, ZE; Ekimova, IV; Guzhova, IV; Pastukhov, IuF; Romanova, IV | 1 |
| Beseler, C; Cavalieri, EL; Rogan, E; Saeed, M; Yang, L; Zahid, M | 1 |
| Carroll, CB; Hanemann, CO; Zajicek, JP; Zeissler, ML | 1 |
| Gu, L; Sun, L; Wang, S; Yang, H; Yuan, J; Zhang, H; Zhu, J | 1 |
| Abuladze, N; Bragin, A; Cascio, D; Damoiseaux, R; Faull, K; Pushkin, A; Schibler, MJ; Tsirulnikov, K | 1 |
| Benke, S; Broeskamp, F; Büttner, S; Callewaert, G; Carmona-Gutierrez, D; D'hooge, P; Eisenberg, T; Faes, L; Franssens, V; Freudenberger, P; Ghillebert, R; Habernig, L; Harger, A; Kourtis, N; Kroemer, G; Madeo, F; Pieber, TR; Reichelt, WN; Ruli, D; Sigrist, SJ; Tavernarakis, N; Winderickx, J | 1 |
| Johnson, WM; Mieyal, JJ; Wilson-Delfosse, AL | 1 |
| Jantas, D; Konieczny, J; Kuśmierczyk, J; Lasoń, W; Lenda, T; Lorenc-Koci, E; Roman, A | 1 |
| Belizaire, R; Björklund, LM; Isacson, O; Jenner, P; McNaught, KS; Olanow, CW | 1 |
| Jenner, P; McNaught, KS; Olanow, CW; Perl, DP; Shashidharan, P | 1 |
| Berger, K; Cookson, MR; Eberhardt, O; Engelender, S; Farrer, MJ; Gerhardt, E; Hernandez, D; Holzmann, C; Kachergus, J; Krüger, R; Li, L; Marx, FP; Riess, O; Ross, CA; Schöls, L; Schulz, JB; Strauss, KM | 1 |
| Feng, J; Jiang, Q; Ren, Y; Zhao, J | 1 |
| Cho, Y; Choi, HJ; Hwang, O; Lee, SY | 1 |
| Bennett, JP; Onyango, IG; Tuttle, JB | 1 |
| Kabuta, T; Setsuie, R; Wada, K | 1 |
| Maeda, S; Ogita, K; Yamamuro, A; Yoshioka, Y | 1 |
| Inayat-Hussain, SH; Ross, D; Zafar, KS | 1 |
| Le, W; Li, L; Li, X; Ming, M; Peng, C; Yang, D | 1 |
| Sens, DA; Shavali, S | 1 |
| Chen, S; Du, Y; Huang, K; Le, W; Li, X; Yang, D; Zhang, X | 1 |
| Bonham, CC; Davisson, VJ; Hindupur, J; Liu, F; Nguyen, JL; Rochet, JC; Ruf, KJ; Schieler, JL; Wood, KV; Zhu, J | 1 |
| Hochman, A; Melamed, E; Offen, D; Sternin, H; Ziv, I | 1 |
| Ferrándiz, ML; Hernández, AI; Martínez, M; Martínez, N | 1 |
| Amarnath, V; Graham, DG; Kravtsov, V; Montine, TJ; Picklo, MJ; Zhang, J | 1 |
| Martínez Banaclocha, M | 1 |
| Hermida-Ameijeiras, A; Labandeira-Garcia, JL; Méndez-Alvarez, E; Muñoz-Patiño, AM; Soto-Otero, R | 1 |
| Delogu, MR; Desole, MS; Enrico, P; Esposito, G; Grella, G; Miele, E; Miele, M; Migheli, R; Mura, MA; Serra, PA | 1 |
| Jenner, P; McNaught, KS | 1 |
| Dawson, TM; Engelender, S; Igarashi, S; L Dawson, V; Rao, RK; Ross, CA; Sawa, A; Tanaka, Y; Tanzi, RE; Wanner, T | 1 |
| Larsen, KE; Rideout, HJ; Stefanis, L; Sulzer, D | 1 |
| Amarnath, V; Montine, TJ; Olson, SJ; Ou, JJ; Sidell, KR; Zhang, Y | 1 |
| Kim, JR; Kwon, KS; Lee, SR; Rhee, SG; Yoon, HW | 1 |
| Elkon, H; Melamed, E; Offen, D | 1 |
4 review(s) available for acetylcysteine and Parkinson Disease
| Article | Year |
|---|---|
[Dopaminergic neuroprotection via Nrf2-ARE pathway activation: identification of an activator from green perilla leaves].
Topics: Acetylcysteine; Animals; Antioxidant Response Elements; Cell Death; Chalcones; Dopaminergic Neurons; NF-E2-Related Factor 2; Oxidative Stress; Oxidopamine; Parkinson Disease; Perilla; Proteasome Endopeptidase Complex; Rats | 2013 |
Cysteine Network (CYSTEINET) Dysregulation in Parkinson's Disease: Role of N-acetylcysteine.
Topics: Acetylcysteine; Aging; Amino Acid Transport System y+; Brain; Cysteine; Energy Metabolism; Glutathione; Homeostasis; Humans; Metabolic Networks and Pathways; Oxidation-Reduction; Parkinson Disease; Protein Processing, Post-Translational; Reactive Oxygen Species | 2016 |
Dysregulation of glutathione homeostasis in neurodegenerative diseases.
Topics: Acetylcysteine; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Friedreich Ataxia; Glutathione; Homeostasis; Humans; Huntington Disease; Neurodegenerative Diseases; Parkinson Disease | 2012 |
Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease?
Topics: Acetylcysteine; Adenosine Triphosphate; Corpus Striatum; Humans; Mitochondria; Models, Neurological; NAD(P)H Dehydrogenase (Quinone); Neuroprotective Agents; Oxidative Phosphorylation; Parkinson Disease; Reactive Oxygen Species; Substantia Nigra | 1999 |
3 trial(s) available for acetylcysteine and Parkinson Disease
| Article | Year |
|---|---|
Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress.
Topics: Acetylcysteine; Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Brain; Catalase; Female; Glutathione; Humans; Male; Middle Aged; Models, Biological; Oxidative Stress; Parkinson Disease | 2018 |
N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease.
Topics: Acetylcysteine; Administration, Oral; Aged; Antioxidants; Dopamine Plasma Membrane Transport Proteins; Drug Monitoring; Female; Functional Neuroimaging; Humans; Infusions, Intravenous; Male; Parkinson Disease; Putamen; Symptom Assessment; Treatment Outcome | 2019 |
N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data.
Topics: Acetylcysteine; Aged; Antioxidants; Caudate Nucleus; Cell Differentiation; Cell Survival; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Female; Human Embryonic Stem Cells; Humans; Male; Mesencephalon; Middle Aged; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Pilot Projects; Putamen; Rotenone; Single Photon Emission Computed Tomography Computed Tomography; Tissue Culture Techniques | 2016 |
78 other study(ies) available for acetylcysteine and Parkinson Disease
| Article | Year |
|---|---|
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
Topics: Acetylcysteine; Active Transport, Cell Nucleus; Adrenergic Agents; Animals; Cell Nucleus; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Glutathione; Hydrogen Peroxide; Imidazoles; Models, Biological; NF-E2 Transcription Factor; Oxidants; Oxidative Stress; Oxidopamine; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; PC12 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyridines; Rats; Reactive Oxygen Species; Ubiquitin | 2007 |
Synthesis and biological evaluation of clovamide analogues with catechol functionality as potent Parkinson's disease agents in vitro and in vivo.
Topics: Apoptosis; Catechols; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Structure-Activity Relationship; Tyrosine | 2019 |
N-acetylcysteine decreases dopamine transporter availability in the non-lesioned striatum of the 6-OHDA hemiparkinsonian rat.
Topics: Acetylcysteine; Animals; Antioxidants; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Nortropanes; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley | 2022 |
Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.
Topics: Acetylcysteine; Aldehyde Dehydrogenase; Animals; Dopamine; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Rotenone; Selegiline | 2023 |
3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; alpha-Synuclein; Antioxidants; Cell Line; Copper; Dopamine; Humans; Monoamine Oxidase; Monophenol Monooxygenase; Oligodendroglia; Oxidation-Reduction; Parkinson Disease; Protein Binding; Protein Conformation; Tolcapone | 2020 |
Potential Role of N-Acetyl-Cysteine in the Cysteine Proteome in Parkinson's Disease?
Topics: Acetylcysteine; Dopamine; Humans; Parkinson Disease; Proteome | 2020 |
Response to "Potential Role of N-Acetyl Cysteine in the Cysteine Proteome in Parkinson's Disease?"
Topics: Acetylcysteine; Dopamine; Humans; Oxidative Stress; Parkinson Disease; Proteome | 2020 |
Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Dopamine; Dopaminergic Neurons; Humans; Iron; Iron Chelating Agents; Neuroprotective Agents; Parkinson Disease; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Substantia Nigra; Ubiquitin | 2020 |
Accelerated habitual learning resulting from L-dopa exposure in rats is prevented by N-acetylcysteine.
Topics: Acetylcysteine; Animals; Antioxidants; Behavior, Addictive; Behavior, Animal; Conditioning, Operant; Dopamine; Dopamine Agents; Glutamic Acid; Habits; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Long-Evans | 2020 |
Cytokinin Plant Hormones Have Neuroprotective Activity in In Vitro Models of Parkinson's Disease.
Topics: Acetylcysteine; Caspase 3; Caspase 7; Cell Death; Cell Differentiation; Cell Line, Tumor; Cytokinins; Glutamic Acid; Humans; Isoquinolines; Models, Biological; Neurons; Neuroprotective Agents; Oxidative Stress; Oxygen; Parkinson Disease; Plant Growth Regulators; Superoxides | 2021 |
Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
Topics: Acetylcysteine; Age Factors; Animals; Calcium-Binding Proteins; Cysteine Proteinase Inhibitors; Disease Models, Animal; Forelimb; Glial Fibrillary Acidic Protein; Glutamate Decarboxylase; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Microinjections; Neuroglia; Neurotransmitter Agents; Parkinson Disease; Psychomotor Performance; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase | 2017 |
[
Topics: Acetylcysteine; Animals; Brain; Disease Models, Animal; Fluorine Radioisotopes; Image Processing, Computer-Assisted; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Tetrabenazine | 2017 |
Parkinson's disease-related DJ-1 functions in thiol quality control against aldehyde attack in vitro.
Topics: Acetylcysteine; Aldehydes; Amino Acid Sequence; beta-Alanine; Coenzyme A; Glutathione; HeLa Cells; Humans; Inactivation, Metabolic; Lactic Acid; Mutant Proteins; Mutation; Parkinson Disease; Protein Deglycase DJ-1; Pyruvaldehyde; Recombinant Proteins; Sequence Homology, Amino Acid; Structural Homology, Protein; Sulfhydryl Compounds | 2017 |
Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.
Topics: Acetylcysteine; Analysis of Variance; Animals; Choline O-Acetyltransferase; Cysteine Proteinase Inhibitors; Disease Models, Animal; Galanin; Male; Neurons; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2018 |
Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.
Topics: Acetylcysteine; Animals; Biogenic Monoamines; Cysteine Proteinase Inhibitors; Parkinson Disease; Positron-Emission Tomography; Proteasome Endopeptidase Complex; Radioligand Assay; Swine; Swine, Miniature; Time Factors | 2018 |
Topics: Acetylcysteine; Animals; Antiparkinson Agents; Brain; Female; Metabolome; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2019 |
Adaptive changes in autophagy after UPS impairment in Parkinson's disease.
Topics: Acetylcysteine; Animals; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Humans; Male; Membrane Proteins; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Parkinson Disease; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Signal Transduction; TOR Serine-Threonine Kinases; Ubiquitin | 2013 |
An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson's disease.
Topics: Acetylcysteine; Analysis of Variance; Animals; Antibodies, Monoclonal; Calcium-Binding Proteins; Cell Count; Choline O-Acetyltransferase; Cholinergic Neurons; Cysteine Proteinase Inhibitors; Disease Models, Animal; Forelimb; Functional Laterality; Image Processing, Computer-Assisted; Laser Capture Microdissection; Magnetic Resonance Imaging; Male; Membrane Proteins; Motor Activity; Muscle Proteins; Nerve Degeneration; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Phosphopyruvate Hydratase; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2015 |
Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
Topics: Acetylcysteine; Animals; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Dopamine; Humans; Male; Mice; Neuroblastoma; Neurons; Neuroprotective Agents; Parkinson Disease; Pentacyclic Triterpenes; Proteasome Inhibitors; Rats; Rats, Wistar; Substantia Nigra; Triterpenes | 2014 |
Differential protein profile of PC12 cells exposed to proteasomal inhibitor lactacystin.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Cell Death; Cytoplasm; Heat-Shock Proteins; Inclusion Bodies; Parkinson Disease; PC12 Cells; Proteasome Inhibitors; Proteome; Rats; Tyrosine 3-Monooxygenase | 2014 |
Critical cysteines in Akt1 regulate its activity and proteasomal degradation: implications for neurodegenerative diseases.
Topics: Acetylcysteine; Animals; Calmodulin; Cell Line, Tumor; Cell Survival; Cysteine; Down-Regulation; Glutaredoxins; Humans; Mice; Mutagenesis, Site-Directed; Mutation; Parkinson Disease; Phosphorylation; Proteasome Endopeptidase Complex; Protein Disulfide Reductase (Glutathione); Protein Phosphatase 2; Proteolysis; Proto-Oncogene Proteins c-akt; Signal Transduction | 2014 |
α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Cell Death; Humans; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Parkinson Disease; Rats, Wistar | 2014 |
TNF-α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells.
Topics: Acetylcysteine; Adenosine Triphosphate; Amino Acid Chloromethyl Ketones; Cell Death; Cell Line; Dopaminergic Neurons; Electron Transport Complex I; Free Radical Scavengers; Humans; MicroRNAs; Mitochondria; Parkinson Disease; Protease Inhibitors; Tumor Necrosis Factor-alpha | 2015 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; GABA-A Receptor Agonists; Homovanillic Acid; Locomotion; Male; Muscimol; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats, Wistar; Receptors, GABA-A; Substantia Nigra | 2015 |
Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease.
Topics: Acetylcysteine; Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Blood-Brain Barrier; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Parkinson Disease | 2015 |
Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Cell Count; Choline O-Acetyltransferase; Cholinergic Neurons; Disease Models, Animal; Dopaminergic Neurons; Male; Microglia; Neurons; Parkinson Disease; Parkinsonian Disorders; Pars Compacta; Pedunculopontine Tegmental Nucleus; Protein Aggregation, Pathological; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2016 |
Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
Topics: Acetylation; Acetylcysteine; Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dopaminergic Neurons; Glial Cell Line-Derived Neurotrophic Factor; Histone Deacetylase Inhibitors; Histones; Male; Neuroprotective Agents; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley; Up-Regulation; Valproic Acid | 2015 |
Parkinsonian toxin-induced oxidative stress inhibits basal autophagy in astrocytes via NQO2/quinone oxidoreductase 2: Implications for neuroprotection.
Topics: Acetylcysteine; Adaptor Proteins, Signal Transducing; Animals; Antioxidants; Astrocytes; Astrocytoma; Autophagy; Benzhydryl Compounds; Enzyme Inhibitors; Formamides; Mice; Microtubule-Associated Proteins; Neuroprotection; Neuroprotective Agents; Neurotoxins; NF-E2-Related Factor 2; Oxidative Stress; Paraquat; Parkinson Disease; Phagosomes; Quinone Reductases; Sequestosome-1 Protein; Signal Transduction; Vacuoles | 2015 |
Cell death caused by the synergistic effects of zinc and dopamine is mediated by a stress sensor gene Gadd45b - implication in the pathogenesis of Parkinson's disease.
Topics: Acetylcysteine; Animals; Antigens, Differentiation; Apoptosis; Cell Cycle Proteins; Cell Death; Dopamine; Drug Synergism; Free Radical Scavengers; Gene Knockdown Techniques; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred C57BL; Necrosis; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; PC12 Cells; Rats; Zinc | 2016 |
Plastic changes at corticostriatal synapses predict improved motor function in a partial lesion model of Parkinson's disease.
Topics: Acetylcysteine; Animals; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Male; Mice, Inbred C57BL; Motor Activity; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Parkinsonian Disorders; Pars Compacta; Post-Synaptic Density; Rotarod Performance Test; Synapses | 2017 |
Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's disease.
Topics: Acetylcysteine; Adenosine Triphosphate; Animals; Benzoquinones; Brain; Disease Models, Animal; Dopamine; Free Radical Scavengers; Free Radicals; Humans; Hydrogen Peroxide; Mitochondria; Parkinson Disease; Rats; Sodium-Potassium-Exchanging ATPase | 2008 |
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement.
Topics: Acetylcysteine; Animals; Autophagy; Cells, Cultured; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Protein Folding; Rats; Sirolimus | 2008 |
Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Animals; Blotting, Western; Cell Nucleus; Dopamine; Dopamine Agents; Enzyme Activation; Excitatory Amino Acid Antagonists; Immunohistochemistry; Immunoprecipitation; Ketamine; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 10; Neostriatum; Neurons; Parkinson Disease; Protein Transport; Quinoxalines; Tyrosine 3-Monooxygenase | 2009 |
[Dual effects of different concentrations of alpha-synuclein on the neurotoxicity of 6-hydroxydopamine in SH-SY5Y cells].
Topics: Acetylcysteine; alpha-Synuclein; Apoptosis; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Neurons; Neuroprotective Agents; Neurotoxins; Oxidopamine; Parkinson Disease | 2009 |
Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration.
Topics: Acetylcysteine; Animals; Apoferritins; Cation Transport Proteins; Chelation Therapy; Corpus Striatum; Cysteine Proteinase Inhibitors; Cytoprotection; Dopamine; Gene Expression Regulation; Genetic Therapy; Iron Metabolism Disorders; Mice; Mice, Transgenic; Nerve Degeneration; Neurons; Parkinson Disease; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Substantia Nigra | 2010 |
Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis.
Topics: Acetylcysteine; Apoptosis; Chloroquine; Gene Knockdown Techniques; Humans; Hydrogen Peroxide; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Leupeptins; Lysosomes; Parkinson Disease; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Serine-Threonine Kinases | 2010 |
The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
Topics: Acetylcysteine; Animals; Blotting, Western; Canavanine; Cell Survival; Cells, Cultured; Cysteine Proteinase Inhibitors; Dopamine; Immunohistochemistry; Locus Coeruleus; Male; Nerve Degeneration; Neurons; Oxidative Stress; Parkinson Disease; Proteasome Endopeptidase Complex; Protein Folding; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Uncoupling Agents | 2010 |
Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
Topics: Acetylcysteine; Animals; Autophagy; Benzothiazoles; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Dopamine Agonists; Glial Cell Line-Derived Neurotrophic Factor; Male; Mice; Mice, Inbred C57BL; Microglia; Motor Activity; Neurons; Neuroprotective Agents; Parkinson Disease; Pramipexole; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Dopamine D3; Substantia Nigra; Ubiquitin | 2010 |
Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics.
Topics: Acetylcysteine; Animals; Autophagy; Brain; Cell Death; Cell Line; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mitochondria; Mutant Proteins; Neostriatum; Neurons; Oncogene Proteins; Parkinson Disease; Peroxiredoxins; Phenotype; Protein Deglycase DJ-1; Protein Kinases; Reactive Oxygen Species; Ubiquitin-Protein Ligases | 2010 |
Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice.
Topics: Acetylcysteine; Administration, Oral; alpha-Synuclein; Animals; Cytosol; Dietary Supplements; Dopamine; Gene Expression; Glutathione; Humans; Male; Mice; Mice, Transgenic; Motor Activity; Neostriatum; Neuroprotective Agents; NF-kappa B; Parkinson Disease; Protein Transport; Proto-Oncogene Proteins c-sis; Time Factors; Tyrosine 3-Monooxygenase | 2010 |
Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Cell Line, Tumor; Cerebral Cortex; Cycloheximide; Cysteine Proteinase Inhibitors; Humans; Leupeptins; Lewy Bodies; Neurons; Okadaic Acid; Parkinson Disease; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Phosphatase 1; Protein Phosphatase 2; Protein Synthesis Inhibitors; Rabbits; Ubiquitin | 2010 |
The neuroprotective effect of modified Yeoldahanso-tang via autophagy enhancement in models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Animals; Autophagy; Brain; Cell Differentiation; Dopamine; Male; Medicine, Korean Traditional; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Phytotherapy; Plant Extracts; Proteasome Endopeptidase Complex; Proteins; Rabbits; Rats; Ubiquitin | 2011 |
Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Topics: Acetylcysteine; Animals; Blotting, Western; Corpus Striatum; Dose-Response Relationship, Drug; Male; Parkinson Disease; Proteasome Inhibitors; Rats; Rats, Wistar; Substantia Nigra | 2011 |
Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds.
Topics: Acetylcysteine; alpha-Synuclein; Antioxidants; Apigenin; Ascorbic Acid; Deferoxamine; Dose-Response Relationship, Drug; Flavanones; Flavonoids; Humans; Iron Chelating Agents; Microscopy, Confocal; Microscopy, Fluorescence; Molecular Structure; Mutation; Parkinson Disease; Phenols; Polyphenols; Protein Multimerization; Protein Structure, Quaternary; Recombinant Proteins; Spectrometry, Fluorescence; Structure-Activity Relationship | 2011 |
N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse.
Topics: Acetylcysteine; Age Factors; Aged; Analysis of Variance; Animals; Blotting, Western; Cell Count; Cell Death; Disease Models, Animal; Dopamine; Excitatory Amino Acid Transporter 3; Humans; Immunohistochemistry; Mice; Mice, Knockout; Microglia; Motor Activity; Neurons; Oxidative Stress; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; bcl-2-Associated X Protein; Cell Death; Dopamine; Electron Spin Resonance Spectroscopy; Electron Transport Complex I; Free Radicals; Glutathione; Mitochondria; Nitric Oxide; Nitric Oxide Donors; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Reactive Oxygen Species; S-Nitroso-N-Acetylpenicillamine | 2011 |
[Content of chaperon Hsp70 in dopaminergic neurons of the black substance increases in proteasome dysfunstion].
Topics: Acetylcysteine; Aging; Animals; Bacterial Proteins; Biotin; Blotting, Western; Catheterization; Cysteine Proteinase Inhibitors; Disease Models, Animal; Dopamine; HSP70 Heat-Shock Proteins; Humans; Immunohistochemistry; Microinjections; Microscopy, Confocal; Neurons; Parkinson Disease; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Wistar; Substantia Nigra; Tyrosine 3-Monooxygenase; Ubiquitin; Up-Regulation | 2011 |
Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease.
Topics: Acetylcysteine; Antioxidants; Benzoquinones; DNA Adducts; Dopamine; Humans; Hydrogen-Ion Concentration; Kinetics; Melatonin; Monophenol Monooxygenase; Parkinson Disease; Resveratrol; Stilbenes; Thioctic Acid | 2011 |
Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Cell Death; Cell Survival; Dose-Response Relationship, Drug; Dronabinol; Herbicides; Humans; Neurons; Neuroprotective Agents; Oxidative Stress; Paraquat; Parkinson Disease; Receptor, Cannabinoid, CB1; Tumor Cells, Cultured; Up-Regulation | 2012 |
N-acetylcysteine protects against apoptosis through modulation of group I metabotropic glutamate receptor activity.
Topics: Acetylcysteine; Animals; Apoptosis; Cell Line; Cell Survival; Disease Models, Animal; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Free Radical Scavengers; Methoxyhydroxyphenylglycol; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptors, Metabotropic Glutamate; Staurosporine | 2012 |
N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for?
Topics: Acetylcysteine; Animals; Drug Therapy, Combination; Glutathione; Humans; Levodopa; Models, Theoretical; Oxidative Stress; Parkinson Disease | 2012 |
Inhibition of aminoacylase 3 protects rat brain cortex neuronal cells from the toxicity of 4-hydroxy-2-nonenal mercapturate and 4-hydroxy-2-nonenal.
Topics: Acetylation; Acetylcysteine; Acrolein; Aldehydes; Alzheimer Disease; Amidohydrolases; Aminooxyacetic Acid; Animals; Cerebral Cortex; Enzyme Inhibitors; Male; Neurons; Parkinson Disease; Rats; Rats, Wistar | 2012 |
The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Apoptosis; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcium; Calcium-Transporting ATPases; Humans; Manganese; Models, Biological; Molecular Chaperones; Oxidative Stress; Parkinson Disease; Phosphorylation; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2013 |
The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions.
Topics: Acetylcysteine; Cell Death; Cell Differentiation; Cell Survival; Cells, Cultured; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Drug Interactions; Humans; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Pentacyclic Triterpenes; Rotenone; Time Factors; Tretinoin; Triterpenes | 2013 |
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.
Topics: Acetylcysteine; Animals; Cysteine Endopeptidases; Dopamine; Dose-Response Relationship, Drug; Inclusion Bodies; Multienzyme Complexes; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Rats; Rats, Sprague-Dawley; Striatonigral Degeneration; Substantia Nigra | 2002 |
Aggresome-related biogenesis of Lewy bodies.
Topics: Acetylcysteine; Antigens; Brain; Canavanine; Centrosome; Dose-Response Relationship, Drug; Golgi Apparatus; HSP70 Heat-Shock Proteins; Humans; Immunohistochemistry; Lewy Bodies; Lewy Body Disease; Nerve Tissue Proteins; Neurons; Parkinson Disease; Peptide Hydrolases; Protein Folding; Synucleins; Tubulin; Ubiquitins | 2002 |
Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease.
Topics: Acetylcysteine; Adult; Aged; alpha-Synuclein; Amino Acid Sequence; Carrier Proteins; Case-Control Studies; Cell Death; Cells, Cultured; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Female; Green Fluorescent Proteins; Humans; Luminescent Proteins; Male; Middle Aged; Molecular Sequence Data; Multienzyme Complexes; Mutation; Nerve Tissue Proteins; Neurons; Parkinson Disease; Proteasome Endopeptidase Complex; Recombinant Fusion Proteins; Staurosporine; Synucleins; Ubiquitin-Protein Ligases | 2003 |
Parkin is recruited to the centrosome in response to inhibition of proteasomes.
Topics: 3T3 Cells; Acetylcysteine; Animals; Brain; Centrosome; Chlorocebus aethiops; COS Cells; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Immunohistochemistry; Mice; Microtubules; Multienzyme Complexes; Parkinson Disease; Proteasome Endopeptidase Complex; Protein Binding; Protein Denaturation; Protein Folding; Rats; Tubulin; Ubiquitin-Protein Ligases; Ubiquitins | 2003 |
Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Benzoquinones; Biopterins; Cell Death; Cell Line; Cytosol; Dimethyl Fumarate; Dopamine; Drug Resistance; Enzyme Inhibitors; Fumarates; Ketanserin; Lipid Peroxidation; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Mice; Monoamine Oxidase Inhibitors; Neurons; Oxidative Stress; Parkinson Disease; Substantia Nigra; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2005 |
Activation of p38 and N-acetylcysteine-sensitive c-Jun NH2-terminal kinase signaling cascades is required for induction of apoptosis in Parkinson's disease cybrids.
Topics: Acetylcysteine; Aged; Antioxidants; Apoptosis; Cell Survival; Cells, Cultured; Collagen Type XI; DNA, Mitochondrial; Enzyme Activation; Enzyme Inhibitors; Female; Gene Amplification; Humans; Hybrid Cells; JNK Mitogen-Activated Protein Kinases; Male; Middle Aged; NF-kappa B; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Signal Transduction; Up-Regulation | 2005 |
Does proteasome [corrected] inhibition decrease or accelerate toxin-induced dopaminergic neurodegeneration?
Topics: Acetylcysteine; Animals; Apoptosis; Cysteine Proteinase Inhibitors; Dopamine; Humans; Leupeptins; Lewy Bodies; Neurotoxins; Oxidopamine; Parkinson Disease; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protective Agents; Rats; Substantia Nigra | 2005 |
Involvement of endoplasmic reticulum stress on the cell death induced by 6-hydroxydopamine in human neuroblastoma SH-SY5Y cells.
Topics: Acetylcysteine; Activating Transcription Factor 6; Adrenergic Agents; Animals; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Free Radical Scavengers; Heat-Shock Proteins; Humans; Molecular Chaperones; Neoplasm Proteins; Neuroblastoma; Oxidopamine; Parkinson Disease; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Transcription Factor CHOP; Tunicamycin; Ubiquitin | 2006 |
A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132.
Topics: Acetylcysteine; Animals; Apoptosis; Caspases; Cell Line, Transformed; Cysteine Proteinase Inhibitors; Dopamine; Dose-Response Relationship, Drug; Enzyme Activation; Leupeptins; Mesencephalon; Nerve Degeneration; Neurons; Oxidative Stress; Parkinson Disease; Proteasome Endopeptidase Complex; Rats; Reactive Oxygen Species; Substantia Nigra | 2007 |
Glial cell-derived neurotrophic factor protects against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation.
Topics: Acetylcysteine; Animals; Apoptosis; Caspase 3; Cells, Cultured; Dopamine; Endoplasmic Reticulum; Enzyme Activation; Glial Cell Line-Derived Neurotrophic Factor; Humans; Inclusion Bodies; Nerve Degeneration; Neurons; Parkinson Disease; Proteasome Inhibitors; Rats; Recombinant Proteins | 2007 |
Synergistic neurotoxic effects of arsenic and dopamine in human dopaminergic neuroblastoma SH-SY5Y cells.
Topics: Acetylcysteine; Anticarcinogenic Agents; Antioxidants; Arsenites; Cell Line, Tumor; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Synergism; Humans; Isothiocyanates; Necrosis; Neuroblastoma; Neurons; Parkinson Disease; Sulfoxides; Thiocyanates | 2008 |
Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
Topics: Acetylcysteine; Animals; Cysteine Proteinase Inhibitors; Disease Models, Animal; Dopamine; Glial Cell Line-Derived Neurotrophic Factor; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinases; Nerve Degeneration; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Phosphatidylinositol 3-Kinases; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Random Allocation; Signal Transduction; Substantia Nigra | 2008 |
Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Antioxidants; Blotting, Western; Cell Death; Cells, Cultured; Cysteine Proteinase Inhibitors; Dopamine; Humans; Leupeptins; Mesencephalon; Methionine Sulfoxide Reductases; Mice; Neurons; Oxidation-Reduction; Oxidoreductases; Parkinson Disease; Rats; Rotenone; Uncoupling Agents; Vitamin E | 2008 |
Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Dithiothreitol; Dopamine; Glutathione; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Rats; Sulfhydryl Compounds | 1996 |
Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Apoptosis; Catechols; Dopamine; Neurotoxins; Parkinson Disease; Rats; Sulfides; Tumor Cells, Cultured | 2000 |
N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease.
Topics: Acetylcysteine; Aging; Animals; Electron Transport Complex I; Free Radical Scavengers; Mice; Mitochondria; NADH, NADPH Oxidoreductases; Parkinson Disease; Sulfhydryl Compounds; Synapses; Synaptosomes | 2000 |
Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Cysteine; Female; Free Radical Scavengers; Glutathione; Hydrogen Peroxide; Neurons; Oxidation-Reduction; Oxidopamine; Oxygen Consumption; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics | 2000 |
Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Ascorbic Acid; Chlorides; Chromatography, High Pressure Liquid; Corpus Striatum; Dialysis Solutions; Dopamine; Homovanillic Acid; Infusion Pumps; Levodopa; Male; Manganese; Manganese Compounds; Microdialysis; Movement; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Wistar; Time Factors; Uric Acid | 2000 |
Proteasomal function is impaired in substantia nigra in Parkinson's disease.
Topics: Acetylcysteine; Aged; Cysteine Endopeptidases; Dihydroxyphenylalanine; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Hydrolysis; Levodopa; Lewy Bodies; Male; Multienzyme Complexes; Parkinson Disease; Peptide Hydrolases; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Substantia Nigra; Ubiquitins | 2001 |
Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Apoptosis; Blotting, Western; Caspase 3; Caspase 9; Caspases; Cyclosporine; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Gene Expression Regulation; Immunoenzyme Techniques; Membrane Potentials; Mitochondria; Multienzyme Complexes; Mutation; Nerve Tissue Proteins; Parkinson Disease; PC12 Cells; Proteasome Endopeptidase Complex; Rats; Synucleins; Tetracycline; Transfection | 2001 |
Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells.
Topics: Acetylcysteine; alpha-Synuclein; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Cell Differentiation; Cyclic AMP; Cysteine Endopeptidases; Immunoblotting; Immunohistochemistry; Inclusion Bodies; Lewy Body Disease; Multienzyme Complexes; Nerve Tissue Proteins; Neuroprotective Agents; Oligopeptides; Parkinson Disease; PC12 Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Rats; Synucleins; Ubiquitins | 2001 |
Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Animals; Brain; Cells, Cultured; Corpus Striatum; Cysteine; Dopamine; Esters; Female; Fetus; Humans; In Vitro Techniques; Male; Mesencephalon; Microdialysis; Nerve Degeneration; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Sprague-Dawley; Synaptosomes | 2001 |
Oxidation of proteinaceous cysteine residues by dopamine-derived H2O2 in PC12 cells.
Topics: Acetylcysteine; Animals; Apoptosis; Catalase; Creatine Kinase; Cysteine; Dopamine; Glyceraldehyde-3-Phosphate Dehydrogenases; Hydrogen Peroxide; Isoenzymes; Nerve Tissue Proteins; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Phospholipase C gamma; Protein Disulfide-Isomerases; Protein Isoforms; Rats; Thioredoxin-Disulfide Reductase; Type C Phospholipases | 2002 |
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.
Topics: Acetylcysteine; Animals; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Free Radical Scavengers; Humans; Leupeptins; Lewy Bodies; Methionine; Models, Neurological; Multienzyme Complexes; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease; PC12 Cells; Proteasome Endopeptidase Complex; Rats; Substantia Nigra; Sulfur Radioisotopes; Sympatholytics; Ubiquitins | 2001 |